Delcath Systems, Inc. (DCTH)

5,44 +0,04 (+0,74%) Börsenschluss: 04:00PM EDT

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States
212 489 2100
https://www.delcath.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 76

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Gerard J. Michel MBA, MS	CEO & Director	727,97k	N/A	1963
Ms. Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer	N/A	N/A	1980
Dr. Martha S. Rook Ph.D.	Chief Operating Officer	N/A	N/A	1970
Mr. David Hoffman	General Counsel, Corporate Secretary & Chief Compliance Officer	N/A	N/A	N/A
Dr. Johnny John M.D.	Senior Vice President of Clinical Operations & Medical Affairs	472,16k	N/A	1965
Dr. Vojislav Vukovic M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1967

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.